215 related articles for article (PubMed ID: 15492788)
1. Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma.
Cagliero E; Ferracini R; Morello E; Scotlandi K; Manara MC; Buracco P; Comandone A; Baroetto Parisi R; Baldini N
Oncol Rep; 2004 Nov; 12(5):1023-31. PubMed ID: 15492788
[TBL] [Abstract][Full Text] [Related]
2. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
3. Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance.
Avnet S; Lemma S; Cortini M; Pellegrini P; Perut F; Zini N; Kusuzaki K; Chano T; Grisendi G; Dominici M; De Milito A; Baldini N
Oncotarget; 2016 Sep; 7(39):63408-63423. PubMed ID: 27566564
[TBL] [Abstract][Full Text] [Related]
4. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
5. Pre-treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin.
Scotlandi K; Serra M; Manara MC; Lollini PL; Maurici D; Del Bufalo D; Baldini N
Int J Cancer; 1994 Jul; 58(1):95-101. PubMed ID: 7912235
[TBL] [Abstract][Full Text] [Related]
6. Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925.
Yang X; Yang P; Shen J; Osaka E; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Br J Cancer; 2014 Jun; 110(12):2896-904. PubMed ID: 24853187
[TBL] [Abstract][Full Text] [Related]
7. Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15.
Uchiyama-Kokubu N; Watanabe T; Cohen D
Jpn J Cancer Res; 2001 Oct; 92(10):1116-26. PubMed ID: 11676863
[TBL] [Abstract][Full Text] [Related]
8. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
9. ABCG1 and Pgp identify drug resistant, self-renewing osteosarcoma cells.
Roundhill EA; Jabri S; Burchill SA
Cancer Lett; 2019 Jul; 453():142-157. PubMed ID: 30910588
[TBL] [Abstract][Full Text] [Related]
10. A bioassay for the activity of PSC 833 in human serum for modulation of P-glycoprotein-mediated multidrug resistance.
Uchiyama-Kokubu N; Watanabe T; Nakajima M
Anticancer Drugs; 2000 Aug; 11(7):583-90. PubMed ID: 11036963
[TBL] [Abstract][Full Text] [Related]
11. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
[TBL] [Abstract][Full Text] [Related]
12. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
Stein U; Walther W; Shoemaker RH
J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin induced expression of P-glycoprotein in a canine osteosarcoma cell line.
Mealey KL; Barhoumi R; Rogers K; Kochevar DT
Cancer Lett; 1998 Apr; 126(2):187-92. PubMed ID: 9585065
[TBL] [Abstract][Full Text] [Related]
14. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Sonneveld P; Marie JP; Huisman C; Vekhoff A; Schoester M; Faussat AM; van Kapel J; Groenewegen A; Charnick S; Zittoun R; Löwenberg B
Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance modification using pulsing electromagnetic field stimulation for multidrug resistant mouse osteosarcoma cell line.
Hirata M; Kusuzaki K; Takeshita H; Hashiguchi S; Hirasawa Y; Ashihara T
Anticancer Res; 2001; 21(1A):317-20. PubMed ID: 11299755
[TBL] [Abstract][Full Text] [Related]
16. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.
Duan Z; Zhang J; Ye S; Shen J; Choy E; Cote G; Harmon D; Mankin H; Hua Y; Zhang Y; Gray NS; Hornicek FJ
BMC Cancer; 2014 Sep; 14():681. PubMed ID: 25236161
[TBL] [Abstract][Full Text] [Related]
17. Tetrandrine prevents multidrug resistance in the osteosarcoma cell line, U-2OS, by preventing Pgp overexpression through the inhibition of NF-κB signaling.
Lu Y; Li F; Xu T; Sun J
Int J Mol Med; 2017 Apr; 39(4):993-1000. PubMed ID: 28260091
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
Lehne G; Rugstad HE
Br J Cancer; 1998 Sep; 78(5):593-600. PubMed ID: 9744497
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance and malignancy in human osteosarcoma.
Scotlandi K; Serra M; Nicoletti G; Vaccari M; Manara MC; Nini G; Landuzzi L; Colacci A; Bacci G; Bertoni F; Picci P; Campanacci M; Baldini N
Cancer Res; 1996 May; 56(10):2434-9. PubMed ID: 8625324
[TBL] [Abstract][Full Text] [Related]
20. Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells.
Shen F; Bailey BJ; Chu S; Bence AK; Xue X; Erickson P; Safa AR; Beck WT; Erickson LC
J Pharmacol Exp Ther; 2009 Aug; 330(2):423-9. PubMed ID: 19423841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
